

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/253713 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 515/18 (2006.01)
C07D 401/04 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01) A61K 31/4439 (2006.01)
C07D 513/04 (2006.01)

(21) International Application Number:

PCT/EP2022/064481

(22) International Filing Date:

27 May 2022 (27.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/PL2021/000030

01 June 2021 (01.06.2021)

PL

(71) Applicant: **CAPTOR THERAPEUTICS S.A.** [PL/PL];
ul. Dunska 11, 54-427 Wrocław (PL).

(72) Inventors: **COTTENS, Sylvain**; Traubenweg 34, 4108
Witterswil (CH). **DREWNIAK-SWITALSKA, Magda**;
Włokniarzy 7/34, 54-062 Wrocław (PL). **KACZANOWS-
KA, Katarzyna**; ul. Teczowa 89/50, 53-601 Wrocław


(PL). **TOMCZYK, Tomasz**; ul. Polna 54E/8, 55-002
Kamieniec Wrocławski (PL). **TRACZ, Andrzej**; ul. Pol-
na 20B, 51-361 Wilczyce (PL). **WALCZAK, Michał**;
ul. Mieszczanska 13/4, 50-201 Wrocław (PL). **WOJCIK,
Karolina**; ul. Bajana 42C/7, 54-129 Wrocław (PL).

(74) Agent: **COOLEY (UK) LLP**; 22 Bishopsgate, London
Greater London EC2N 4BQ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE
AND TARGET MCL-1 PROTEIN



(57) Abstract: A compound of formula (I); [MCL-1 ligand moiety] - [linker] - [ligase ligand moiety] (I); or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C), and its use in the treatment of cancer.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*